IE
CYTK icon

Israel Englander’s Cytokinetics CYTK Stock Holding History

Israel Englander’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-107,900
Closed -$7.11M – 5957
2026
Q1 		$7.11M Buy
+107,900
New +$6.86M ﹤0.01% 2551
2024
Q2 		– Sell
-18,300
Closed -$1.28M – 5992
2024
Q1 		$1.28M Sell
18,300
-39,200
-68% -$3.03M ﹤0.01% 4089
2023
Q4 		$4.8M Buy
+57,500
New +$2.08M ﹤0.01% 2823
2021
Q3 		– Sell
-91,800
Closed -$1.82M – 6851
2021
Q2 		$1.82M Buy
91,800
+45,200
+97% +$1.06M ﹤0.01% 4077
2021
Q1 		$1.08M Buy
+46,600
New +$995K ﹤0.01% 4140

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's CYTK Position: Q2 2026 in Review

Israel Englander increased its Cytokinetics (CYTK) stake by 12% in Q2 2026, buying an estimated $844K and bringing the position to 109,717 shares worth $9.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2346.

Israel Englander first reported a position in CYTK in Q2 2013 and has held it in 49 quarters since. The position peaked at $100M in Q4 2023. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Israel Englander held 109,717 shares of Cytokinetics worth $9.35M as of Q2 2026.
  • Israel Englander bought 11,758 Cytokinetics shares in Q2 2026, an estimated $844K.
  • Cytokinetics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2346 holding.
  • Israel Englander first reported a position in Cytokinetics in Q2 2013 and has held it in 49 quarters since.
  • Israel Englander's Cytokinetics position peaked at $100M in Q4 2023.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.